NovoCure Q1 net revenue up 13% to $138.5M; METIS trial meets endpoint, FDA decision on lung cancer PMA expected H2 2024

NovoCure Ltd

2024-Q1 EPS reported -$0.36 revenue$138,503,000

Net revenue $138.5M (+13% YoY); net loss $38.8M ($0.36 loss per share); adjusted EBITDA -$4.6M.
Active patients 3,845; prescriptions received 1,643 (+10% YoY).
METIS Phase 3 met primary endpoint (brain metastases from NSCLC); will be presented at ASCO.
LUNAR PMA for Optune Lua in NSCLC: Day 100 FDA meeting productive, decision expected H2 2024.
Entered $400M senior secured credit facility with Pharmakon Advisors (non-dilutive).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

NovoCure Ltd reported quarter ended March 31, 2024 results: revenue $138.5 million, net income $38.8 million, EPS $0.36.

Period: quarter ended March 31, 2024
Revenue: $138.5 million
Net income: $38.8 million
EPS: $0.36
Result: reported results

Exact text from the filing

Total net revenues for the quarter were $138.5 million, an increase of 13% compared to the same period in 2023.

View on SEC.gov

268 earnings releases filed in the last 30 days. Browse all earnings releases →

NovoCure Ltd filing history →

Source: SEC EDGAR

accession 0001645113-24-000014

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.